Sjögren's Syndrome Market 2025 | Industry Developments, Future Growth, Share & Industry Insights | Haleon Group, Teva Pharmaceutical, Horizon Therapeutics, Bausch Health Companies Inc.

Sjögren's Syndrome Market reached US$ 201.70 million in 2023, increasing to US$ 207.84 million in 2024, and is expected to reach US$ 277.82 million by 2033, growing at a CAGR of 3.3% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Sjögren's Syndrome Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/sjogrens-syndrome-market?sg

Key Players: Amgen, F. Hoffmann-La Roche Ltd., Pfizer Inc., Haleon Group of Companies, AstraZeneca, Sanofi SA, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Horizon Therapeutics plc, and Bausch Health Companies Inc.

USA - Industry Development:

✅ Novartis Announces Phase III Success for Ianalumab
On August 11, 2025, Novartis reported that both NEPTUNUS-1 and NEPTUNUS-2 trials for ianalumab met their primary endpoints, demonstrating a statistically significant reduction in disease activity for Sjögren's disease.

✅ Vor Bio to Present Phase 3 Data at ACR Convergence 2025
On September 29, 2025, Vor Bio announced that clinical data from their Phase 3 study of telitacicept in primary Sjögren's disease will be presented as a late-breaking poster at ACR Convergence 2025 in Chicago.

Japan - Industry Development:

✅ RemeGen Submits BLA for Telitacicept in China
On August 13, 2025, RemeGen submitted a Biologics License Application (BLA) to China's National Medical Products Administration for telitacicept in primary Sjögren's disease, marking its fourth approved indication in China.

✅ Emerging Therapies in Clinical Development
As of September 18, 2025, several therapies are under clinical development for Sjögren's Syndrome, including R-2487 by Rise Therapeutics, BMS-986325 by Bristol-Myers Squibb, and VAY736 by Novartis.

Korea - Industry Development:

✅ RemeGen's Telitacicept Achieves Phase III Success
On August 14, 2025, RemeGen's telitacicept met its primary endpoints in a Phase III trial for primary Sjögren's syndrome in China, with a U.S.-based Phase III trial underway.

Europe - Industry Development:

✅ World Sjögren's Day 2025 Highlights Unmet Needs
On July 9, 2025, Sjögren Europe marked World Sjögren's Day 2025, emphasizing the real unmet needs of individuals living with Sjögren's Disease and the importance of awareness through research.

✅ NIH Releases Strategic Plan for Autoimmune Disease Research
On August 28, 2025, the National Institutes of Health released its first-ever NIH-Wide Strategic Plan for Autoimmune Disease Research, marking a significant step forward in enhancing and coordinating federal research on autoimmune diseases, including Sjögren's.

Growth Forecast Projected:

The Global Sjögren's Syndrome Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Sjögren's Syndrome Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=sjogrens-syndrome-market?sg

Key Segments:

By Type (Primary Sjögren's Syndrome, Secondary Sjögren's Syndrome)

By Drug Class(Corticosteroids, Immunosuppressive agents, Monoclonal antibodies, Others)

By Route of Administration(Oral, Injectable)

By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Sjögren's Syndrome producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Sjögren's Syndrome revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/sjogrens-syndrome-market?sg

FAQ's

Q1: What is the current size of the Sjögren's Syndrome Market?

A: The Sjögren's Syndrome Market stood at US$ 207.84 million in 2024 and is set to experience remarkable growth, reaching US$ 277.82 million by 2033 as organizations increasingly prioritize cloud-based security solutions.

Q2: How fast is the Sjögren's Syndrome Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 3.3% from 2025-2033

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele,

This release was published on openPR.